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The principal goals of health care are to help people “live 
longer and live better,” that is, to optimize both survival and 
health. In the American Heart Association’s (AHA) special 
report, “Defining and setting national goals for cardiovas-
cular health promotion and disease reduction: the American 
Heart Association’s strategic Impact Goal through 2020 and 
beyond,” the AHA set the following goal:
“By 2020, to improve the cardiovascular health of 
all Americans by 20% while reducing deaths from 
 cardiovascular diseases and stroke by 20%.”1
The emphasis on improving cardiovascular health is laud-
able, yet it raises the question of how cardiovascular health is 
best measured. Indeed, the metrics of cardiovascular health 
have not been well delineated compared with other cardiovas-
cular mortality and morbidity outcomes.
The AHA’s strategic goals primarily focus on ideal health 
behaviors (eg, not smoking) and ideal health factors (eg, 
blood pressure control) as metrics of cardiovascular health.1 
Although these are of clear import, they do not directly 
address the World Health Organization’s definition of health 
as “… a state of complete physical, mental and social well-
being.”2 Moreover, the Institute of Medicine identified patient-
centered care as 1 of the 6 domains of high-quality health 
care, wherein patient-centered care supports clinicians in 
“attending to their patients’ physical and emotional needs, and 
maintaining or improving their quality of life.”3 The Patient-
Centered Outcomes Research Institute emphasizes the goal 
of “focusing on outcomes that people notice and care about 
such as survival, function, symptoms, and health related qual-
ity of life.”4 Recent concepts of value in health care and the 
“triple aim” center on improving patients’ health and experi-
ence with health care while reducing costs; each reinforces 
the importance of assessing the impact of disease and medical 
treatment on patients’ functional status and quality of life.5,6 
The definition of health and concepts of patient-centered care 
directly support the measurement of patient health status as a 
key metric of cardiovascular health.
Accordingly, the goal of this scientific statement is to review 
and advocate for patient-reported health status as a measure of 
cardiovascular health. The present statement defines patient health 
(Circulation. 2013;127:2233-2249.)
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status in the context of cardiovascular health and then describes 
key aspects of patient health status surveys, with an emphasis 
on currently available cardiovascular disease (CVD)–specific 
instruments. Subsequent sections synthesize the current literature, 
providing examples of studies that have used cardiovascular 
patient–reported health status measures both as outcomes and as 
independent (predictor) variables. Areas of need for additional 
research are highlighted throughout. The statement then describes 
potential uses of cardiovascular patient–reported health status 
in clinical decision making and population health surveillance, 
noting barriers that need to be overcome to realize this potential. 
Ultimately, the present statement is intended to support the AHA’s 
efforts to promote inclusion of patient health status as a measure 
of cardiovascular health when setting organizational goals and 
advocating for cardiovascular health (Table 1).
2. Executive Summary
Patient health status includes 3 components: symptom burden, 
functional status, and health-related quality of life (HRQL; 
Figure).7 Symptom burden includes the types and frequency 
of symptoms a patient may have as a manifestation of dis-
ease or from medical treatments (eg, symptoms from side 
effects of medications). Functional status includes physical, 
mental/emotional, and social function. Finally, HRQL is the 
perception of discrepancy between actual and desired func-
tional status and overall impact of disease on well-being for 
a given patient.
Although there are performance tests that can help quan-
tify physical functional status (eg, exercise treadmill test-
ing), most aspects of patient health status are best captured 
by patient self-report. HRQL reflects how an individual views 
and adapts to his or her symptom burden, functional limita-
tions, and prognosis, as well as how patients perceive their 
overall health. Because each person differentially experiences 
the degree to which symptoms and functional limitations of 
disease and medical therapies impact their well-being, HRQL 
can only be accurately quantified by patient self-report.
An important corollary is that HRQL cannot be accurately 
inferred by anatomic or physiological tests. Myriad prior stud-
ies have shown that measures such as left ventricular ejection 
Table 1. Top Things to Know
•   Improving cardiovascular health is a central goal of cardiovascular care and a specific aim of the American Heart Association’s strategic goals; however, measures 
of cardiovascular health beyond mortality and morbidity outcomes have not been well specified.
•   Patient-reported health status, which includes symptom burden, functional status, and HRQL, is an important measure of health.
•   Validated patient health status surveys, including disease-specific instruments for patients with cardiovascular disease, allow for the quantification of this critical, 
patient-centered outcome.
•   Cardiovascular patient health status surveys have been used successfully in clinical trials and other research studies to quantify treatment benefits with regard to 
symptoms, functional status, and HRQL; however, they remain underutilized.
•   In addition to cardiovascular disease–specific factors contributing to worse patient health status (eg, amount of angina in coronary artery disease), other key 
cofactors must be recognized (eg, comorbid depression). There are also special considerations in the measurement of health status in cohorts such as the elderly.
•   Patient-reported health status is an independent predictor of subsequent mortality, cardiovascular events, hospitalization, and costs of care. This has potential 
implications for risk adjustment and targeting of healthcare resources.
•   Patient health status data have the potential to inform clinical decision making. In particular, such information can be important for shared decision making.
•   Cardiovascular patient health status assessments can facilitate disease surveillance and quantify populations’ health for entities such as accountable care 
organizations but have not yet been incorporated into population health/disease surveillance efforts. The integration of health status into these activities may 
enhance the patient-centeredness of care and better characterize the impact of healthcare delivery on patient health.
•   Additional research is needed to better understand the determinants of patient health status, the effects of interventions on cardiovascular health, and the most 
effective strategies to incorporate cardiovascular patient health status measurement in clinical practice and disease surveillance.















































Figure. Patient-reported health status. *From 
disease or from medical treatments (eg, side 
effects or complications). Modified from Rums-
feld et al.7 Copyright © 2002, American Heart 
Association, Inc. Modified from Spertus et al8;  
reprinted with permission from Elsevier. 
 Copyright © 2002, American Heart Journal. 
Modified from Wilson and Cleary9; reprinted 
with permission of the American Medical Asso-
ciation. Copyright © 1995, American Medical 
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fraction, B-type natriuretic peptide, and extent of coronary 
artery disease (CAD) by coronary angiography are either 
weakly or not associated with HRQL.7,10–13 This is reflected 
in the experience of most clinicians, in which 2 patients with 
the same diagnosis and test results (eg, heart failure with left 
ventricular ejection fraction of 0.30) may have very different 
symptom burdens, functional capabilities, and quality of life.
To date, the assessment of patient health status in clinical 
practice has been heterogeneous, largely dependent on com-
munication between clinician and patient in a given episode of 
care. Although a given clinician may strive to effectively assess 
the health status of his or her patients, standardized metrics to 
monitor patient health status over time or to compare among 
patients are not routinely implemented in practice. Moreover, 
time constraints may preclude effective assessment of patient 
health status in a given episode of care, and a given patient may 
have multiple care providers. In addition, there may be sig-
nificant discrepancies between provider-assessed and patient-
reported health status.14 Ultimately, each patient is their own 
“gold standard” for their symptom burden, functional limita-
tions, and HRQL. Thus, there is a clear need for the use of 
standardized tools to assess patient-reported health status.
Fortunately, valid patient-reported health status surveys, 
with a basis in the science of psychometrics, have been 
developed, including disease-specific instruments for patients 
with CVD. These instruments quantify symptom burden, 
functional status, and HRQL in a standardized, reproducible, 
and valid fashion. Patient health status surveys have been 
used in clinical studies, including randomized clinical trials, 
to quantify treatment benefits with regard to symptom 
improvement, functional improvements, and improved HRQL. 
However, patient health status surveys remain underused as 
metrics in clinical studies.15
In addition, patient health status is a strong, independent 
predictor of other health outcomes, including mortality, car-
diovascular events, hospitalization, and costs of care.16–18 As 
such, patient health status surveys not only measure health 
outcomes, they also help predict outcomes and quantify 
patient risk above and beyond traditional risk variables such 
as patient demographics, medical history, and physiological 
and anatomic tests. Indeed, patient health status surveys are 
complementary to history, physical, laboratory, and other 
diagnostic tests. Patient health status may therefore be impor-
tant for risk adjustment and may be useful in targeting health-
care resources such as disease management to those with the 
largest health deficits.
Although the goal of many therapeutic interventions is to 
alleviate symptoms, improve functional status, and optimize 
quality of life, patient-reported health status measures are not 
used routinely in clinical practice.7,19 Moreover, patient health 
status data are not generally available to inform public health 
or CVD surveillance efforts.20 HRQL was included as a mea-
sure of cardiovascular health in the AHA’s strategic impact 
goals in recognition of the fact that cardiovascular health 
extends beyond measures of disease prevalence and risk fac-
tors to include the impact of CVD on patient functional status 
and well-being.1 However, it was listed as a secondary metric 
of cardiovascular health given the challenges of widespread 
measurement of HRQL and availability of HRQL data. The 
future of patient health status as a measure of cardiovascu-
lar health, beyond its use in research, hinges on the degree to 
which it becomes incorporated in clinical practice and disease 
surveillance efforts.
3. Patient Health Status Surveys
Patient-reported health status can generally be defined as 
the impact of disease(s) and medical treatments on function 
and well-being as reported by the patient.7 More specifically, 
stemming from the conceptual quality-of-life model proposed 
by Wilson and Cleary,9 patient health status has 3 principal 
components: symptom burden, functional status (eg, physical, 
mental, social), and HRQL, which reflects how an individ-
ual person perceives their functional limitations and overall 
impact of their health on their well-being.8,9 The components 
of patient-reported cardiovascular health status are displayed 
in the Figure.
Over the past several decades, using the science of psycho-
metrics, multiple standardized patient health status surveys 
have been developed. Key psychometric properties of these 
surveys include reliability, responsiveness, interpretability, 
and validity.21 The best health status surveys have undergone 
reproducibility testing (to ensure the survey results are stable 
when the measure is repeated in a patient in whom health 
status has not changed), are sensitive to clinical change (ie, 
the survey scores change appropriately when clinical status 
changes), and are interpretable (ie, the survey can be scored in 
a way to quantify patient health status, and changes in survey 
scores over time are also interpretable).
Of note, there is no true criterion validity for patient-
reported health status, because it is not a proxy for other 
metrics but instead is a direct assessment of the patient’s per-
spective of the impact of disease on their function and HRQL. 
However, most standardized patient health status surveys have 
demonstrated predictive or correlative association with other 
metrics (eg, correlation between patient-reported physical 
functional limitations and exercise treadmill testing) as part of 
their development. As a result of this body of scientific work, 
easily administered and standardized patient health status sur-
veys are available to collect structured information from the 
patient that cannot be accurately quantified any other way.
Two major types of patient health status surveys are general, 
or “generic,” and disease specific. General health status surveys 
quantify overall functional status and well-being but do not 
ask about symptoms or functional limitations attributable to a 
particular disease. Perhaps the best-known example, the Short-
Form 36, or SF-36 (and the related shorter versions, such as 
the SF-12), has 36 questions that relate to 8 health status 
scales (vitality, physical functioning, bodily pain, general 
health perceptions, physical role functioning, emotional role 
functioning, social role functioning, and mental health) and 
2 summary scores (physical and mental component summary 
scores).22 Another example, the National Institutes of Health’s 
Patient-Reported Outcomes Measurement Information 
System (PROMIS), provides online general patient health 
status surveys to quantify “physical, mental and social well-
being,” with branching logic to minimize the number of 
questions depending on the answers provided.23 Other general 
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(eg, assigning a number from 0–1 as the personal value of 
their overall state of health) and thus are particularly useful 
in the estimation of quality-adjusted life-years in economic 
analyses.24 General health status surveys are particularly useful 
for comparisons among populations (eg, comparing patients 
with CVD to healthy cohorts or those with other chronic 
diseases). However, general surveys do not quantify symptom 
burden (eg, angina) or functional limitations related to CVD 
and are less sensitive to clinical change (over time or after 
a therapeutic intervention), and their clinical interpretation is 
more difficult than that for disease-specific instruments.
Because the present scientific statement is specifically 
about cardiovascular health, the primary focus here is on 
CVD-specific patient health status surveys. Disease-specific 
patient health status surveys quantify symptom burden, func-
tional limitations, and HRQL related to a specific condition. 
Cardiovascular-specific health status surveys exist for patients 
with CAD/angina, heart failure, atrial fibrillation, stroke, and 
peripheral artery disease (PAD). CAD health status surveys 
have been used in studies of patients with chronic stable 
CAD, those undergoing coronary revascularization, and after 
acute myocardial infarction (MI). Heart failure health status 
surveys have been used in studies of outpatients with chronic 
heart failure, after hospitalization for heart failure, and among 
patients with valve disease in which the principal symptom-
atic manifestation is similar to chronic heart failure (eg, dys-
pnea). PAD-specific surveys have been used in patients with 
claudication and critical limb ischemia to determine perceived 
changes in community-based walking, symptoms, physical 
and emotional functioning, and quality of life in response to 
pharmacological, exercise, or revascularization interventions.
Examples of validated CVD-specific patient health sta-
tus surveys include the MacNew Heart Disease Health 
Related Quality of Life Questionnaire and Seattle Angina 
Questionnaire (SAQ) for patients with CAD,25,26 the Minnesota 
Living with Heart Failure Questionnaire and the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) for patients with 
heart failure or valve disease,27,28 the Atrial Fibrillation Effect 
on Quality of Life for patients with atrial fibrillation,29 the 
Stroke Impact Scale and Stroke-Specific Quality of Life Scale 
for stroke patients,30,31 and the Peripheral Artery Questionnaire 
and Vascular Quality of Life Questionnaire for patients with 
PAD.32,33 Table 2 lists characteristics of some of the currently 
available and most commonly used CVD-specific patient 
health status surveys for CAD, atrial fibrillation, heart failure, 
and PAD.
Given the focus of the present scientific statement, we 
only listed surveys that capture aspects of all 3 of the prin-
cipal patient health status domains (ie, symptom burden, 
functional status, and HRQL) in Table 2. However, there are 
other validated surveys that capture single domains of patient 
health status, such as symptom-specific (eg, pain) or function-
specific (eg, physical functional status) questionnaires. Well-
known examples of the latter include the Walking Impairment 
Questionnaire for patients with PAD and the Duke Activity 
Status Index for patients with CAD.48,49
The CVD-specific health status surveys listed in Table 2 
range from ≈10 to 60 questions. Most emphasize symptoms 
referable to the given disease (eg, angina in patients with 
CAD), physical functional limitations related to those symp-
toms, and questions about well-being/quality of life. Some 
include questions about topics such as self-efficacy, mental 
health status/anxiety, treatment concerns and satisfaction, or 
sexual functioning. Administration times generally range from 
5 to 15 minutes. There are no standard guidelines in choosing 
one of these instruments over another. The choice will often 
be driven by the primary condition of interest (eg, heart fail-
ure) and may be influenced by factors such as the length and 
content of the individual surveys or familiarity with an instru-
ment. Often, general and disease-specific health status surveys 
are administered simultaneously in studies.
Although most of these surveys were designed for patient 
self-administration on paper, studies using these surveys have 
also used other modalities such as interview administration 
(eg, nurse interview of the patient), phone, and Web-based 
administration. In general, evidence supports that differen-
tial modes of administration do not lead to systematic differ-
ences or bias in results50; however, because these surveys were 
validated as they are written, 2 issues must be considered. 
First, when a survey is being administered (eg, read aloud) 
to a patient, it is important that the questions and the answer 
choices be read precisely as written. Second, surveys such as 
those listed in Table 2 were developed and validated by use of 
formal psychometric testing; any perturbation of the content 
potentially threatens the underlying validity and reliability. 
The instruments should be administered and scored in the way 
they were validated, and it is generally not acceptable to alter 
the content or order of the existing standardized surveys with-
out further psychometric and clinical validation work to sup-
port these alterations. Understanding and addressing potential 
language or cultural and health literacy barriers to successful 
administration of health status surveys remains an important 
area of research. Of note, as listed in Table 2, many of the 
currently available standardized patient health status surveys 
have now been translated and validated in a number of other 
languages in addition to English.
All health status surveys provide a standardized scoring 
algorithm. In general, there are domain scores (eg, symptom 
score, physical function score, quality-of-life score) based on 
answers to questions related to each domain; in addition, for 
most instruments, a summary score that reflects the overall 
health status of the patient related to that disease/condition can 
be calculated. Importantly, a number of the currently avail-
able disease-specific health status surveys provide the clini-
cally important difference/change in scores, which facilitates 
interpretation for use in clinical trials, registries, and clinical 
practice.51,52 However, the clinical interpretation of health 
status survey scores remains a barrier to the use of these 
instruments in clinical practice and decision making. This is 
further considered in section 7, “Clinical Use of Health Status 
Assessments.”
There is no standard of timing of administration of patient 
health status surveys (eg, when to administer them in relation 
to a given healthcare episode) nor a standard frequency of 
repeat measurement. In general, because the surveys were 
designed to support patient self-administration, a given patient 
should be in a health state sufficient to answer the questions 
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Table 2. Characteristics of Some Currently Available Cardiovascular Disease–Specific Patient Health Status Surveys
Instrument
Population in Which 
Validated
# of Items 
















27 Physical limitations (14); 
emotional (14); social functioning 
(13)
Both subscales and summary score 
are interpreted as scores between 
1 and 7; lower scores are better. 
Minimal significant change score: 



























19 Physical limitation (9); angina 
stability (1); angina frequency (2); 
treatment satisfaction (4); quality 
of life/disease perception (3)
Both subscales and summary 
score are interpreted as scores 
between 0 and 100; higher scores 
are better.
Significant change scores: Physical 
limitations change score, ≥8 
points; angina frequency change 
score, ≥20 points; quality-of-life 












35 Physical activity (12); insecurity 
(9); emotional reaction (4); 
dependency (3); diet (3); 
concerns about medications (2); 
side effects (2)
Subdomain scores are interpreted 
as scores between 0 and 100; 










Chronic stable angina 
patients
37 Four symptom subscales: angina 
(5); shortness of breath (5); 
ankle swelling (3); and tiredness 
(3). Five functional limitation 
subscales: mobility (4); social life 
and leisure activities (3); activities 
within the home (4); concerns (3); 
and worries and gender (3)
Unknown range of scores.
Symptoms subscales: mild, 
moderate, severe.
Limitations subscales: no limitation, 
mild, moderate, severe.
Chinese Lewin et al36










of quality of 
life aspects)
Health and functioning (15); 
socioeconomic (8); psychosocial/
spiritual (7); family (5)
Subdomain scores and summary 
score are interpreted as scores 












AF-QoL Stable atrial 
fibrillation patients
18 Psychological (7); physical (8); 
sexual activity (3)
Subscale and summary score are 
interpreted as scores between 0 and 
100; higher score is better; minimal 
significant change score=12













42 Symptoms (5); social functioning 
(10); physical functioning 
(9); emotional functioning 
(7); treatment concerns (8); 
treatment satisfaction (3)
Subscale and summary score are 
interpreted as scores between 0 
and 100; higher scores are better. 
Summary score excludes items 
on treatment satisfaction. Change 
summary score of 9.8 corresponds 
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Table 2. (Continued)
Instrument
Population in Which 
Validated
# of Items 













 6 Dyspnea (2); limitations in daily 
life related to atrial fibrillation 
(1); discomfort related to atrial 
fibrillation (1); fatigue related 
to atrial fibrillation (1); anxiety 
related to atrial fibrillation (1)
Item-level scores on scale from 
0–10. Overall score from 0–60; 








NYHA class III 
patients in a clinical 
trial with pimobendan














23 Physical limitation (6); symptoms 
(8); self-efficacy (2); social 
limitation (4); quality of life (3)
Overall summary score and 












with heart failure in 
RCT of digoxin
16 Dyspnea (5); fatigue (4); 
emotional (7)
16–122, Worst to best; higher 
score is better
Chinese Guyatt  
et al42,43
Quality of Life 
Questionnaire 




NYHA class II/III 
symptoms in the 
Metoprolol in Dilated 
Cardiomyopathy 
(MDC) trial
26 Psychological (7); physical 
activity (7); life dissatisfaction (5); 
somatic symptoms (7)








PAD patients after 
endovascular therapy; 
exercise training
20 Most symptomatic leg (1); 
physical limitations (6); symptom 
stability (1); symptoms (3); 
treatment satisfaction (3); quality 
of life (3); social function (3)
Subscale and summary scores 
0–100; higher score is better.
Clinically meaningful change=8 
points.










ischemic rest pain, 
tissue loss)
25 Pain (4); symptoms (4); activities 
(8); social well-being (2); 
emotional well-being (7)
Subscale and summary score range 













Strength (4); memory (7); 
emotions (9); communication 
(7); ADL/IADL (10); mobility (10); 
hand function (4); participation 
(8); single item: perceived 
recovery from stroke
Domain scores range: 0–100; 
higher scores indicate better 
function. Four physical domain 
scores can be combined to create a 
composite physical domain score.
Group clinically important 
difference of the physical domains: 
Strength=9.2; ADL/IADL=5.9; 












Mobility (6); energy (3); upper 
extremity function (5); work/
productivity (3); mood (5); self-
care (5); social roles (5); family 
roles (3); vision (3); language (5); 
thinking (3); personality (3)
Domain scores range 1–5; higher 
score represents more normal 
function. The group clinically 
important differences of the 
mobility, self-care, and upper 
extremity function domains are 1.5, 






ADL indicates activities of daily living; CABG, coronary artery bypass graft surgery; DC, direct current; IADL, instrumental activities of daily living; NYHA, New York 
Heart Association; PAD, peripheral artery disease; PTCA, percutaneous transluminal coronary angioplasty; and RCT, randomized controlled trial.
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surveys have been administered successfully in hospital, 
clinic, and home/community settings, as well as before 
and after procedures and other healthcare episodes. Some 
studies, particularly in stroke populations, have used proxy 
assessments (eg, by spouse/family members) of patient health 
status.53 Assessment of health status to evaluate a procedure 
or to compare therapies or outcomes of care delivery should 
be performed at “baseline” (ie, before the procedure or the 
intervention being evaluated) and repeated at some subsequent 
time point. In general, health status cannot be accurately 
assessed retrospectively.
4. Health Status Outcomes in 
Clinical Trial Populations
With increasing recognition of the availability of standardized, 
validated patient health status surveys as described above, the 
use of patient-reported health status measures in cardiovascu-
lar research is gaining momentum. To date, patient health sta-
tus surveys have been included in hundreds of cardiovascular 
clinical studies, including randomized clinical trials, observa-
tional studies (eg, prospective cohort studies), and assessments 
of quality improvement interventions in clinical practice.
Patient health status surveys have been included as out-
comes in dozens of clinical trials of cardiovascular therapeu-
tics. Many of these findings have been of central importance 
to understanding the comparative effectiveness of different 
care strategies. For example, the PARTNER (Placement of 
Aortic Transcatheter Valve) trial randomized patients with 
symptomatic, severe aortic stenosis who were not candi-
dates for surgical valve replacement to transcatheter aortic 
valve replacement or usual therapy.54 Patient health status 
was assessed at baseline and then reassessed at 1, 6, and 12 
months with the KCCQ and SF-12. At baseline, mean KCCQ 
summary scores and SF-12 summary scores were low in both 
groups, which confirms poor patient health status among 
patients with advanced aortic stenosis. Although the KCCQ 
summary score and SF-12 scores improved over time in both 
groups, the extent of improvement was significantly greater 
with transcatheter aortic valve replacement therapy than with 
usual care at 1, 6, and 12 months. Importantly, the differences 
between groups at each time point during follow-up were clin-
ically and statistically significant. Thus, PARTNER provided 
strong evidence that transcatheter aortic valve replacement 
significantly improved the symptom burden, functional status, 
and quality of life of patients who underwent the procedure.
As another example, the COURAGE (Clinical Outcomes 
Utilizing Revascularization and Aggressive Drug Evaluation) 
trial compared a strategy of percutaneous coronary interven-
tion (PCI) with optimal medical therapy to optimal medical 
therapy alone among patients with stable CAD.55 Because the 
goal of PCI among patients with stable coronary disease is to 
improve symptoms and functional status, rather than improve 
survival, patient health status was a critical outcome. Patient 
health status was measured in the COURAGE trial with the 
SAQ, and patients randomized to PCI had small but signifi-
cant benefits in terms of less angina frequency, better physi-
cal functional status, and better quality of life over 6 to 24 
months after randomization; however, health status outcomes 
were equivalent at 36 months. This highlights that serial 
measurement of patient health status can quantify the effects 
of treatment strategies over time with regard to symptom sta-
tus, functional status, and quality of life.
In other examples in clinical trial populations, patient-
reported health status outcomes have been compared for 
carotid stenting versus carotid endarterectomy (similar 1-year 
health status outcomes) and for PCI versus coronary artery 
bypass graft (CABG) surgery (improvement in health sta-
tus for both, with small benefits in angina burden for CABG 
surgery)56,57; among patients receiving continuous-flow left 
ventricular assist devices (significant improvements in health 
status when preimplantation was compared with postim-
plantation status at 24 months)58; after hospitalization for 
advanced heart failure (demonstrating a pattern of recovery 
of health status over 6 months)59; among patients undergoing 
PCI for chronic total occlusions (showing that only patients 
who are symptomatic at baseline have an improvement in 
health status outcomes)60; in an evaluation of the benefit of 
exercise training in patients with heart failure (modest but sta-
tistically significant improvements in health status with exer-
cise training)61; and in an evaluation of surgical ventricular 
reconstruction in conjunction with CABG surgery along with 
an economic analysis (no health status benefit for surgical 
ventricular reconstruction and increased healthcare costs).62
Although patient-reported health status surveys are increas-
ingly incorporated into clinical trials, they remain underused.15 
When they are included, it is often only as secondary mea-
sures or as “add-on” substudies, akin to cohort studies embed-
ded within clinical trial populations, and are thus frequently 
only collected on a subset of the overall clinical trial popula-
tion. Given that a primary goal of many medical therapies is to 
improve symptoms, functional status, or HRQL, stronger con-
sideration of patient health status as a primary study outcome 
is warranted. Similarly, “health delivery research” will often 
use randomized designs to evaluate care-delivery strategies 
or comparative effectiveness in clinical practice.63 Improving 
patient health status will be a primary goal, and thus should be 
a primary outcome, of many of these studies.
5. Health Status Outcomes: Observational 
Studies and Special Populations
Patient health status surveys have been collected in a sizeable 
number of observational (eg, prospective cohort and cross-
sectional) studies. Although a comprehensive review of this lit-
erature is beyond the scope of the present scientific statement, 
studies capturing patient-reported health status in cardiovascular 
populations have evaluated (1) patient characteristics associated 
with health status, ranging from demographic factors, cardio-
vascular history and severity of disease, and coexisting medical 
conditions; (2) patient health status before, during and/or after 
cardiovascular therapeutic interventions such as PCI or car-
diac rehabilitation; (3) psychosocial and behavioral factors and 
patient health status among patients with CVD or those under-
going cardiovascular procedures; and (4) patient-reported health 
status as a predictor of other health outcomes such as mortality.
As examples of observational study findings, a number of 
studies have measured patient health status outcomes after 
acute MI. These studies found that 1 in 5 patients had angina 
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associated with worse functional status and quality of life, as 
well as worse patient satisfaction.64,65 In addition, potentially 
modifiable factors such as smoking and depression were asso-
ciated with patient-reported angina burden after acute MI.64 
Also, older patients, despite a higher mortality, had lower 
symptom burden and better HRQL at 1 year after MI than 
younger patients.66–68
Overall, there is a surprising paucity of research on the 
determinants of patient health status outcomes. Examples 
from existing studies demonstrate that the strongest predictors 
of improvement in patient health status are informed by base-
line health status assessments. Specifically, those having the 
largest improvement in angina status after PCI had a higher 
preprocedure angina burden.69 A recent study evaluated pre-
dictors of the combined end point of mortality or persistently 
low health status after heart failure hospitalization.70 Predictor 
variables included low baseline health status (KCCQ score), 
high B-type natriuretic peptide, hyponatremia, tachycardia, 
hypotension, absence of β-blocker therapy, and history of dia-
betes mellitus and arrhythmia. Of interest, predictor variables 
for persistently low health status outcomes were different 
from predictors of mortality and readmission.
Future research is needed in the development of risk models 
and clinical prediction tools for patient health status outcomes 
in cardiovascular populations. It is hoped that modifiable 
factors predictive of patient health status can be targeted for 
interventions; however, formal evaluation of the incorpora-
tion of these risk tools in clinical practice will be necessary to 
demonstrate whether their use can improve patient outcomes. 
Section 7, “Clinical Use of Health Status Assessments,” pro-
vides further discussion of the integration of patient health 
status measures in clinical practice, including limitations of 
evidence in this regard to date.
The following subsections summarize the literature among 
populations that have been key foci for patient health status 
research, including health status and comorbid depression, 
health status in the elderly, health status and sex, and health 
status and race/ethnicity and socioeconomic status. Future 
research directions are highlighted. Section 6, “Health Status 
as a Predictor of Other Health Outcomes,” separately consid-
ers patient health status as a predictor of outcomes.
5.1. Health Status and Depression
Multiple studies have evaluated depression and other factors 
such as anxiety and posttraumatic stress disorder in relation to 
patient health status outcomes in cardiovascular populations. 
The majority of the currently available literature focuses on 
depression and health status in cardiovascular populations. 
Depression is prevalent in cardiovascular populations; ≈20% 
of CAD patients have moderate to severe depressive symp-
toms.71,72 Depressed patients have more frequent angina, more 
physical limitations, less treatment satisfaction, and worse 
quality of life than nondepressed patients. Among patients 
with a similar burden of inducible ischemia, current anxiety 
and depressive symptoms are associated with more frequent 
angina.73 Similar findings are present among patients who 
have experienced an acute coronary syndrome.74,75
Among patients with heart failure, the prevalence of 
depression is even higher (eg, 30% to 35%).76,77 Depressive 
symptoms are a strong predictor of declines in health status 
among outpatients with heart failure.77 Similar associations 
between depression and patient health status have been found 
in patients with atrial fibrillation and PAD.78,79 In contrast, tra-
ditional cardiac disease severity indices (eg, left ventricular 
ejection fraction, myocardial ischemia) are only weakly asso-
ciated with patient-reported health status.10–13 Also, depressive 
symptoms are associated with less of a health status benefit 
with revascularization and predict which patients will show no 
improvement in functional status 6 months after CABG sur-
gery, which highlights depression as a cofactor in the evalua-
tion of treatment recovery.79,80
The sum of literature to date supports that depression is 
common in cardiovascular populations and is strongly asso-
ciated with worse patient health status, above and beyond 
traditional cardiac or clinical variables.81 As such, studies of 
patient health status in cardiovascular populations, and partic-
ularly evaluation of interventions aimed at improving patient 
symptoms, functional status, and quality of life, should assess 
patients for depression. Depression evaluation, with the spe-
cific goal of identifying patients for whom depression treat-
ment may be indicated, is an actionable goal for improving 
health status. Additional research is also needed to identify 
strategies to incorporate depression and patient health status 
assessment in clinical practice, to improve patient outcomes 
(section 7, “Clinical Use of Health Status Assessments”).
5.2. Health Status and the Elderly
The elderly are the fastest-growing segment of the population, 
and CVD is a leading cause of morbidity and mortality in 
older people. The presence of significant comorbidities, cog-
nitive dysfunction, poor social support, and diminished func-
tional status influences both decision making and treatment 
outcomes. Health status assessment is therefore particularly 
important in this population.
As noted previously, elderly survivors of MI experience 
better quality of life than younger MI patients. It was also 
demonstrated that age was not associated with functional 
decline after MI, which addresses potential assumptions 
related to the association between chronological age and 
health status.68 Studies specific to revascularization proce-
dures also suggest that age alone is not a contraindication 
to treatment. The only randomized trial of invasive versus 
medical therapy in elderly patients with CVD (the Trial of 
Invasive Versus Medical Therapy in Elderly Patients [TIME]) 
used health status as the primary end point and found that 
patients >75 years of age benefit more from revascularization 
than from optimized medical therapy.82 These findings are 
complemented by other studies that showed improvements in 
health status after CABG surgery and PCI in elderly patients 
undergoing these procedures.83–85
Patient health status data specific to the elderly for other car-
diovascular conditions are more limited. However, the elderly 
are well represented in studies of transcatheter aortic valve 
replacement for severe aortic stenosis, in which significant, 
persistent improvements in quality of life after this procedure 
over baseline have been demonstrated.54 It is notable, how-
ever, that in cohorts such as that in the PARTNER trial, elderly 
patients were able to complete the KCCQ, and the KCCQ was 
sensitive to change with the procedure and was useful in evalu-
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Conventional aortic valve replacement and other isolated 
cardiac surgeries are also associated with sustained improve-
ments in health status among patients selected to undergo the 
procedure.86
Medical decisions in older patients can be difficult. Frailty, 
a phenotype of vulnerability to stressors and reduced reserves, 
is an important concept that can encompass comorbidity; 
physical function; physiological reserve; social, cognitive, and 
psychological issues; and nutritional status.87 Frailty is preva-
lent among elderly patients with CVD and is associated with 
adverse outcomes.87–89 Although not generally included in risk 
assessment models, frailty has been shown to add significant 
incremental risk information beyond other clinical variables.88 
This frail phenotype may either be driven by underlying heart 
disease, and thus potentially may be amenable to improvement 
by cardiac therapies, or it may be related primarily to noncar-
diac diagnoses, with only minor contribution from underly-
ing cardiac disease. In the latter case, there may be little to 
no benefit from cardiovascular interventions and substantially 
greater concerns about medication or procedural safety.
To date, few studies have focused on frailty and patient 
health status in cardiovascular populations. Not surprisingly, 
existing studies support that patient health status is lower 
among patients with frailty. This suggests another potential 
utility of health status surveys in capturing additional dimen-
sions of risk (ie, risk related to the contribution of frailty to 
lower functional status). Further health status research in the 
elderly should include the design and validation of instruments 
that can better delineate frailty as a component of health status.
5.3. Health Status and Sex
In general, women with CVD have poorer health status than 
men, even after adjustment for baseline risk factor differ-
ences, according to both general and disease-specific assess-
ments.90–98 These differences can be found within 1 month 
after an acute MI, as well as over the longer term.92–94 Women 
treated with CABG surgery, despite recovering similarly to 
men, also have impaired health status compared with men at 
both 6 and 12 months postoperatively.95,96 Sex differences in 
health status have also been reported in heart failure and adult 
congenital heart disease populations.97,98 The determinants of 
health status also appear to differ between the sexes. Psycho-
logical stress and lower social supports are particularly impor-
tant cofactors among women.99 However, sex differences in 
health status remain despite adjustment for baseline risk fac-
tors, depression, and social support. Gender roles and percep-
tions are a pivotal area for future research.100
5.4. Health Status and Race/Ethnicity and 
Socioeconomic Status
Most health status data are from white patients, but some 
information is available for other races and ethnicities. For 
example, the Medical Expenditure Panel Survey assessed 
general health status surveys in the general population.101 
Blacks and Hispanic subjects with coronary heart disease had 
significantly worse health impairments than whites. Greater 
anginal symptoms and functional impairment (as measured by 
the SF-36 and SAQ) were noted among black patients with 
CAD compared with whites in a cohort of patients undergoing 
cardiac catheterization.102 In patients with diabetes mellitus 
and CAD enrolled in the BARI 2D study (Bypass Angioplasty 
Revascularization Investigation 2 Diabetes), clinical symp-
toms influenced self-reported health status among whites more 
than blacks, who were already more likely to rate their overall 
health as poor.103 Similarly, blacks had more angina, worse 
quality of life, and worse physical functioning (as measured 
by the SAQ and the SF-12 physical component summary) 
than white patients 1 year after an acute coronary syndrome.104 
However, in a more recent evaluation of outcomes after acute 
MI, observed differences between black and white patients 
in mortality, rehospitalization, angina burden, and quality of 
life were no longer significant after risk adjustment for both 
baseline patient characteristics and site of care.105 In blacks 
with advanced, decompensated heart failure, ethnicity was not 
associated with HRQL, but depressive symptoms were asso-
ciated with functional impairment.106 Interestingly, Hispanic 
patients with heart failure were found to have better health 
status outcomes than both blacks and whites, which suggests 
cultural differences may be at play.107 An important consider-
ation is the validation of the health status tool in that popula-
tion and the impact of language barriers. Further work needs 
to explore important health status differences among ethnic 
groups, using tools with comprehension and cultural tailor-
ing, to determine the racial and ethnic influences on treatment 
outcomes.
Lower socioeconomic status is associated with worse health 
status, perhaps as a marker of lessened ability to understand, 
access, afford, and communicate with the healthcare system. 
In CABG patients, those who experienced difficulties afford-
ing care reported a worse health status on undergoing CABG 
and 6 months after the procedure.108 These results were repli-
cated in 2 cohorts of outpatients with heart failure. Difficulties 
in obtaining affordable health care were associated with worse 
health status at baseline and at 1-year follow-up compared 
with those who did not report such difficulties,109 and the per-
ception about whether patients’ income met their demands 
was independently associated with lower health status scores 
in another cohort of outpatients with heart failure.110
Patient health status differences noted by race, sex, age, 
comorbidity, and socioeconomic status underscore the var-
ied reasons a particular individual may perceive their health 
state differentially from others. These findings may also help 
identify specific interventions to improve health status in key 
subgroups at risk.
6. Health Status as a Predictor 
of Other Health Outcomes
Although itself an important health outcome, patient health 
status is also an independent risk factor for other health out-
comes, such as mortality. This section summarizes the litera-
ture on patient health status as a risk factor for subsequent 
patient outcomes, as well as potential implications with regard 
to risk adjustment and targeting of healthcare resources.
Dozens of studies have shown that patient health status 
measures are strong, independent predictors of subsequent 
mortality. This is the case both with general health status 
measures and with disease-specific health status measures. As 
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of mortality after CABG surgery,111 scores on the SAQ are 
predictive of both subsequent acute coronary syndrome and 
mortality,112 and scores on the KCCQ, as well as changes in 
score on the KCCQ (ie, a decline of ≥5 points between assess-
ments), are predictive of mortality and hospitalization.113 
KCCQ scores are also predictive of resource use and costs 
among patients with heart failure.18 There has been a paucity 
of research examining the association between patient health 
status and costs of care among cardiovascular populations; 
this is an area of interest for future research.
Of note, patient health status is predictive of other health 
outcomes, including mortality, after adjustment for a broad 
array of more traditional patient demographic, clinical history, 
physiological, and disease severity variables. The magnitude of 
association between patient health status and mortality varies 
depending on the specific health status instrument/survey used, 
but in many studies, patients with lower health status have at 
least twice the risk of subsequent adverse outcomes, above and 
beyond their other demographic and clinical characteristics.
As a corollary, longitudinal patient health status assess-
ments can help identify patients with changes in health sta-
tus, which may be useful for clinical monitoring.51,113 For 
example, patients with heart failure and stable health status 
may need less frequent office visits for titration of medica-
tions or additional testing. However, if a given patient has a 
significant decline in health status, they are at elevated risk 
for an adverse outcome and should be evaluated for the cause 
of the increase in symptom burden or decline in functional 
status or HRQL. Of note, the effectiveness of such poten-
tial clinical practice applications of patient health status 
are unproven and an ongoing focus for quality of care and 
outcomes research; patient health status in clinical practice 
is further considered in section 7, “Clinical Use of Health 
Status Assessments.”
The body of evidence supporting patient health status as 
an independent predictor of health outcomes has potentially 
important implications for risk adjustment. Current clinical risk 
models and quality and performance measures do not include 
or adjust for patient health status. Most clinicians will endorse 
that decisions about clinical therapeutics are often related to 
a patient’s functional status. Indeed, clinical impressions of 
a patient’s functional capacity, frailty, and “wellness” often 
contribute to decision making. Yet these are nonstandardized 
impressions and have not been quantified with standardized 
tools. Patient health status surveys are standardized metrics 
and are predictive of subsequent outcome. Thus, a strong argu-
ment can be made for the collection of patient health status 
information to quantify this risk and for clinical quality and 
performance measures to incorporate patient health status 
measures as part of risk adjustment. Without this, clinicians 
and hospitals caring for patients with worse health status may 
not have their case mix appropriately accounted for in judg-
ments of their quality of care.
Finally, because patient health status is a risk marker for 
adverse outcome (mortality and morbidity) and healthcare 
costs, it may be useful in targeting healthcare resources. 
For example, it may be effective to target interventions such 
as case management, disease management, cardiac reha-
bilitation, home health, or telehealth to patients with low or 
worsening health status. The effectiveness and cost-effective-
ness of targeting health care resources on the basis of patient 
health status remains unproven, however.
7. Clinical Use of Health Status Assessments
Health status measures have high potential to enhance clinical 
care.7,19 To conceptualize the potential role of disease-specific 
health status measures, a useful analogy is to consider them 
as a standardized history that reproducibly assesses patients’ 
symptoms, functional status, and quality of life. In much the 
same way as echocardiography standardized the assessment 
of left ventricular function, compared with the apical impulse, 
S
3
 gallop, and carotid upstrokes, health status surveys can pro-
vide a more precise estimate of a patient’s health status at a 
point in time, as well as track changes over time. Within this 
framework, patient health status measures have the potential to 
support clinical care, evaluate healthcare quality, quantify an 
important component of procedural appropriateness, identify 
patients for prognostic discussions, and serve as a foundation 
for shared medical decision making. These potential applica-
tions are discussed below, including barriers that must be over-
come and additional research needed to fulfill this potential.
An important aspect is the clinical interpretation of patient 
health status survey results. A number of the validated 
health status surveys have determined clinically important 
changes in survey scores. For example, the minimal clini-
cally important score change for the KCCQ is 5 points, with 
10- and 20-point changes reflecting moderate and large clini-
cal changes, respectively.51 In the Eplerenone Post-AMI Heart 
Failure Efficacy and Survival Trial (EPHESUS), even after 
multivariable adjustment for a wide array of clinical variables, 
each 5-point decline in the KCCQ Overall Summary Score on 
serial assessments was associated with a hazard ratio of 1.11 
(95% confidence interval, 1.05–1.17) for subsequent cardio-
vascular death or hospitalization.113
Studies like this suggest how patient health status survey 
scores may be used for clinical monitoring and prognosis; how-
ever, significant barriers remain. There must be clinical famil-
iarity with and understanding of health status survey scores and 
changes in scores (analogous to laboratory test results). Then 
there must be guidance on linked clinical actions to improve 
patient health status, as well as how to weigh the health status 
results alongside other clinical metrics. The interpretation and 
use of patient health status survey results in clinical care is a 
top priority for both research and quality improvement efforts, 
with linked formal evaluation of interventions that use patient 
health status information in clinical care.
Unfortunately, formal evaluations of the use of patient 
health status measures to support clinical practice are limited, 
and the few studies that have evaluated their use to inform 
care have not demonstrated improved outcomes.114 However, 
a nurse practitioner–led angina clinic in which the SAQ was 
used as a foundation for titration of antianginal medica-
tions was able to demonstrate significant improvements in 
patients’ health status compared with those patients before 
enrollment in the clinic and compared with other angina 
patients managed with routine clinical care.115 Although 
more research is needed, assessing patient health status as 
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of health status data, and creating treatment protocols for 
optimizing patients’ health status are potentially important 
strategies for improving care.
There is evidence that there is great variability in the symp-
tom control and quality of life of patients across primary care 
providers. In a national study of outpatients in Australian gen-
eral practitioner clinics, the proportion of each physician’s 
patients who reported weekly or greater angina varied sub-
stantially.116 Among 207 practices, 14% had no patients with 
weekly angina, whereas in 18% of the clinics, more than half 
of the patients reported weekly angina, and in 4%, all of the 
patients reported weekly angina. Importantly, most clinicians 
believed that angina was optimally controlled in their patients, 
which highlights the value of directly assessing health status 
from patients.
To support the routine use of health status as a marker of 
healthcare quality, the American College of Cardiology/AHA/
Physician Consortium for Performance Improvement created 
performance measures for the routine assessment of patients’ 
health status in CAD and heart failure.117,118 In recent updates, 
these entities continued to endorse the assessment of health 
status as a performance measure for public reporting and 
included the results of these assessments as a quality improve-
ment measure. As clinicians begin using these measures more 
routinely, and as tools to simplify their collection, scoring, and 
reporting, such as patient-oriented medical records, evolve, 
they will have great potential to help quantify and improve 
healthcare quality.
The importance of measuring patient health status is under-
scored by the recent development, measuring, and reporting 
of appropriate use criteria for coronary revascularization.119 
Given that a primary purpose of coronary revascularization is 
to improve patients’ health status, clinician-assessed Canadian 
Cardiovascular Society classification is an important element 
in defining the appropriateness of a procedure. A national 
study found that among PCIs performed for stable angina, 
≈12% were classified as inappropriate.120 However, Canadian 
Cardiovascular Society classification has just 4 categories of 
angina burden, there is interoperator variability in assigning 
Canadian Cardiovascular Society classification class, and 
some have raised a concern that clinicians may feel pressured 
to report higher Canadian Cardiovascular Society classifica-
tion classes for their patients to justify appropriateness.121 Use 
of a patient-reported health status measure is more discrimina-
tive for angina burden and less subject to “gaming” and may 
reduce variability in health status assessment across practices. 
Moreover, as suggested by the Australian study referenced 
above, patient-reported health status can also be assessed in 
outpatient clinics to identify potential underuse of revascular-
ization in symptomatic patients.116
As discussed in section 6, “Health Status as a Predictor of 
Other Health Outcomes,” patient health status measures are 
prognostic of health outcomes. Patient health status assess-
ments can serve 2 purposes in this regard. First, risk stratifica-
tion is a cornerstone of cardiovascular care, and higher-risk 
patients are often eligible for more aggressive therapy, such 
as revascularization in coronary disease or defibrillators in 
the setting of heart failure. Another important application of 
patient prognosis is to be able to communicate to patients 
their expected outcomes so that decisions regarding desired 
therapies can be solicited. For example, a prognostic model 
for patients admitted to the hospital that predicts the combined 
end point of death or persistently poor health status within 
the 6 months after discharge was developed recently.70 The 
knowledge, for example, that a patient had a >50% chance of 
dying or never regaining a good quality of life over the next 6 
months could prompt proactive discussions between patients 
and their providers about patient preferences for advanced 
heart failure treatments (eg, left ventricular assist devices or 
transplantation) or more palliative, symptom-directed care. 
The potential role of patient health status survey data in rela-
tion to clinical decision making, including palliative care deci-
sions, is an important area for additional research.122
Beyond the communication of prognosis, there is potential 
to use patient health status as a foundation for shared medical 
decision making in treatment decisions. The field of compara-
tive effectiveness research is designed to examine patient fac-
tors associated with treatment outcomes. When the outcome 
of interest is mortality, the prognostic association of health 
status with survival may support, with additional research, a 
more accurate assessment of a patient’s anticipated survival 
and how that might change as a function of alternative treat-
ments. When the outcome of interest is health status, the 
provision of estimates of health status benefits with differ-
ent treatment approaches may inform the patient’s decision 
making. For example, the benefits of PCI as a supplement to 
medical therapy alone in the COURAGE trial were greater 
for those with worse baseline health status and not significant 
in those without angina or physical or quality-of-life impair-
ments before treatment.55 As prediction models are developed 
for health status outcomes, as currently exist for mortality, 
these can be deployed to support discussions with patients 
about treatment options.
For the potential clinical and quality-of-care applications 
to become realized, practical methods are needed to collect, 
score, and interpret patient health status data. These opera-
tional issues are increasingly addressable in the era of patient 
engagement, advancing health information technology, and 
healthcare reform. First, patients are increasingly engaged 
in their health care and the healthcare system, as evidenced 
by entities such as the Patient-Centered Outcomes Research 
Institute (http://www.pcori.org), the National Quality 
Forum (http://www.qualityforum.org), and Patients Like Me 
(http://www.patientslikeme.com). Each emphasizes the 
importance of measuring and improving patient functional 
and quality-of-life outcomes.
Second, advances in health information technology promise 
increasing access to electronic data, which can include stan-
dardized patient survey data. For example, tablet computers 
or computer kiosks can be used to collect patient health status 
data at the time of a visit (eg, in the waiting room). Moreover, 
the broad availability of computers, Web access, and mobile 
applications on smartphones support the potential for patients 
to complete surveys untethered to specific episodes of care/vis-
its; for example, patients may be prompted by e-mail messages 
with links to the survey or interactive Web programs. Expansion 
of patient health records may be an important mechanism for 
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can then be made available to care providers or healthcare enti-
ties (eg, hospitals or health systems) or for clinical registries or 
research at the patient’s discretion. In all electronic formats, the 
surveys can be scored with results immediately available, and 
these formats support the ability to track over time.
Third, multiple aspects of healthcare reform may support 
the assessment of patient health status data as part of clinical 
care and population health management. Currently, there are 
no direct incentives in the healthcare system for the collec-
tion or use of patient health status data. However, trends in 
healthcare reform promise an emphasis on patient-centered 
outcomes, assessment and promotion of patient well-being, 
and shared decision making, with an emphasis on the impact 
of potential therapies on outcomes including quality of life.
Despite these promising trends, the optimal methods of 
collection and integration of patient health status data into 
clinical practice remain undefined, and whether such integra-
tion improves patient outcomes remains unproven. As such, 
this is a top priority for quality improvement and outcomes 
research. Many of the same questions regarding application of 
patient health status data in clinical practice are applicable to 
the potential role of patient health status in population health 
and disease surveillance.
8. Health Status and Disease Surveillance
Patient health status surveys should be considered for inclusion 
in national surveillance of heart disease and stroke to ensure 
that the surveillance accounts for cardiovascular health as 
reflected in these patient health status assessments.20 Although 
patient health status measures have been included in research, 
they have generally not been implemented for cardiovascular 
surveillance. Surveys by entities such as the Centers for Dis-
ease Control and Prevention have addressed health behav-
iors and risk factors but have not explicitly measured patient 
health status. Patient health status is an essential measurement 
for adequate assessment of the impact of heart disease and 
stroke, as well as of the therapies and interventions for these 
conditions, on patients’ lives. Future efforts toward the estab-
lishment of national surveillance for heart disease and stroke 
should incorporate patient health status assessment and thereby 
directly promote patient-centered care of the highest quality.
The implementation of health status measurement in disease 
surveillance, although critical, will be challenging. The wide-
spread use of any instrument raises the issue of reliability and 
validity across populations and cultures. Although many of 
the currently available patient health status surveys have been 
used in various populations, and some have been validated in 
multiple countries, their utility when collected over time in 
large populations to inform disease surveillance still needs to 
be evaluated. Health literacy is also a potential barrier to cap-
turing patient health status on a truly representative scale. In 
the setting of established CVD, health literacy is associated 
with adverse outcomes.123 Thus, additional research is needed 
to evaluate the optimal methods of using patient health status 
for disease surveillance, including addressing barriers such as 
health literacy.
Another important aspect is choosing the patient health 
status instrument(s) for disease surveillance. As discussed 
in section 3, “Patient Health Status Surveys,” health status 
surveys can be general or disease specific, and the selection 
of the instrument is important to consider with regard to the 
population(s) intended for assessment. General instruments 
have the advantage of broad applicability and allow across-
disease comparisons with the trade-off of less specificity and 
less sensitivity to clinical change over time. Disease-specific 
instruments are reflective of key symptoms (eg, angina burden 
for patients with CAD) and are sensitive to clinical change but 
are not easily comparable across different disease populations, 
and they are not applicable to patients without extant CVD. 
Therefore, strategies for effective disease surveillance using 
patient health status instruments will need to tailor the surveys 
to intended population(s).
Similar to the discussion of capturing patient health status for 
clinical care (section 7), advances in patient engagement, health 
information technology, and health policy should increasingly 
support the operational aspects of collecting patient health 
status for disease surveillance. Currently, integrated health 
systems such as the Veterans Health Administration, Kaiser 
Permanente, and Intermountain Health may be best positioned 
to implement the operational infrastructure to capture patient 
health status for clinical care and population health and then 
contribute these data to disease surveillance efforts. Because 
many aspects of healthcare reform are aligned to move the 
larger US healthcare system toward integrated models of care, 
larger portions of the system may become better positioned to 
routinely capture patient health status data.
For example, in “accountable care organizations,” groups 
of providers organized in an accountable care organization 
receive a share of the savings obtained by providing more 
efficient and effective care.124 A fundamental expectation is 
the tracking of outcomes of system reform in terms of quality 
health care at the population and community level, as well as 
individual patient satisfaction. The ability to track outcomes 
is limited by the lack of tools to measure the effect of care at 
a population or even community level. In addition, there are 
few systems in place that document patient health status over 
time and across organizations. Commitment to an accountable 
care organization will require a common set of quality metrics 
that include measures of patient health status and the informa-
tion technology resources and tools to collect data and provide 
seamless data flow.
One potentially important approach to capturing patient 
health status for population health/disease surveillance and 
clinical care efforts is to leverage existing national cardio-
vascular clinical registry programs, such as Get With The 
Guidelines (http://www.heart.org), the Society of Thoracic 
Surgeons National Database (http://www.sts.org), and the 
National Cardiovascular Data Registry (http://www.ncdr.com). 
Although this will take a commitment to expand the opera-
tional infrastructure of these programs, the basic infra-
structure for clinical data collection with standardized data 
elements and a national data repository with quality-of-care 
assessment already exists. One program, the Transcatheter 
Valve Therapeutics registry (http://www.ncdr.com/TVT), has 
recently committed to capturing the KCCQ at baseline and fol-
low-up along with other clinical registry data for transcatheter 
aortic valve replacement procedures. Moreover, some health 
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national clinical registry programs as part of routine workflow, 
as well as capturing patient-reported measures (eg, via mobile 
applications). This is one model by which patient health status 
data may be collected to support clinical care and population 
health/disease surveillance.
9. Conclusions
Patient-reported health status is an important cardiovascular 
health outcome that includes 3 domains: symptom burden, 
functional status, and HRQL. Patient health status is also pre-
dictive of other health outcomes, including mortality, cardio-
vascular events, hospitalization, and costs of care. As such, 
patient health status is important both as a risk factor and a 
health outcome. Standardized cardiovascular patient health 
status surveys have been developed and used successfully in 
clinical trials and observational studies. Yet these validated 
measures remain underused as measures of cardiovascular 
health in research settings. Cardiovascular patient health sta-
tus measures may also inform clinical decision making, target 
healthcare resources (ie, to those with low or worsening health 
status), and enable accurate surveillance of disease burden. To 
date, this potential has not been realized. The present scien-
tific statement provides an overview of the measurement of 
patient-reported health status, studies in cardiovascular popu-
lations, and future directions for research and reviews the cur-
rent state and key needs for clinical and surveillance uses of 
cardiovascular patient health status. This statement advocates 
for the broader inclusion of patient-reported health status as 
a key measure of cardiovascular health in clinical research, 
clinical practice, and disease surveillance.
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